Can Ozempic Cause Mood Swings? The Neuropsychiatric Data and What Most Providers Miss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic and other semaglutide medications do not cause mood swings through direct neuropsychiatric mechanisms in most patients, but blood sugar fluctuations, rapid weight loss psychology, and unmasking of underlying mood disorders create a complex clinical picture
• The STEP and SUSTAIN trial data show no statistically significant increase in depression or anxiety compared to placebo, with some evidence suggesting mild mood improvement in specific subgroups
• The pattern most providers miss: mood changes on GLP-1 medications cluster around three distinct windows (weeks 1-4, weeks 8-12, and month 6+), each with different underlying mechanisms
• About 2-4% of patients report mood-related symptoms severe enough to discuss with providers, but causality is difficult to establish because weight loss itself is associated with both mood improvement and psychological stress

Direct answer (40-60 words)

Ozempic does not directly cause mood swings in most patients. Clinical trial data shows no significant increase in depression or anxiety versus placebo. However, blood sugar stabilization, caloric restriction, body image changes, and the unmasking of pre-existing mood disorders create indirect pathways where patients attribute mood changes to the medication when the relationship is more complex.

Table of contents

1. What most articles get wrong about GLP-1 medications and mood
2. The mechanism question: does semaglutide cross the blood-brain barrier?
3. What the clinical trial data actually shows
4. The three-window pattern: when mood changes appear and why
5. Blood sugar stability versus mood instability
6. The psychology of rapid weight loss nobody talks about
7. Unmasking versus causing: pre-existing conditions
8. The decision tree: is this the medication or something else?
9. When mood changes mean you should call your provider
10. Comparing semaglutide to tirzepatide for mood effects
11. The compounded semaglutide question
12. FAQ

What most articles get wrong about GLP-1 medications and mood

Most online content makes one of two errors. The first: claiming GLP-1 medications "don't affect mood at all" because the primary trials didn't flag psychiatric adverse events. The second: listing "mood swings" as a common side effect without distinguishing between direct pharmacological effects and the psychological consequences of rapid metabolic change.

Both are wrong because they ignore mechanism.

The accurate statement is this: semaglutide does not cause mood swings through direct receptor-mediated effects on mood-regulating brain regions in the majority of patients. But the medication creates conditions (blood sugar normalization, appetite suppression, rapid weight change, altered eating patterns) that absolutely affect mood through indirect pathways.

The error shows up in patient conversations. A patient reports irritability in week 3 of treatment. One provider says "that's not a known side effect, it must be something else." Another says "yes, mood changes are common, we can reduce your dose." Neither answer is complete.

The correct clinical approach requires asking: when did the mood change start, what else changed at the same time (sleep, caloric intake, blood sugar patterns, life stressors), does the patient have a history of mood disorders, and does the mood change follow one of the three predictable temporal patterns?

The difference matters because the intervention depends on the mechanism. If the mood change is from hypoglycemia in a diabetic patient, the answer is dose adjustment or meal timing. If it's from the psychological stress of body image change, the answer is different. If it's unmasking of undiagnosed bipolar disorder (which rapid weight loss can do), the answer is psychiatric referral.

Lumping all "mood changes on Ozempic" into one category misses the clinical reality that five different mechanisms produce five different presentations requiring five different responses.

The mechanism question: does semaglutide cross the blood-brain barrier?

Semaglutide is a large peptide molecule (4,113 daltons). The blood-brain barrier typically excludes molecules larger than 400 to 500 daltons. So the default assumption would be: semaglutide stays in peripheral circulation and doesn't directly affect the brain.

That assumption is partially wrong.

GLP-1 receptors exist in the brain, particularly in the hypothalamus, area postrema, and nucleus tractus solitarius. These regions regulate appetite, satiety, and reward processing. The area postrema and parts of the hypothalamus sit outside the blood-brain barrier in structures called circumventricular organs, which means circulating semaglutide can bind receptors there directly.

A 2021 study by Gabery et al. published in JCI Insight used radiolabeled semaglutide in primates and found receptor binding in the area postrema, subfornical organ, and median eminence, all circumventricular structures. Minimal binding occurred in mood-regulating regions like the amygdala, prefrontal cortex, or hippocampus.

This matters because the regions semaglutide reaches are appetite and metabolic control centers, not primary mood regulation centers. The neuroanatomical data suggests semaglutide's brain effects are focused on eating behavior and energy homeostasis, not emotional regulation.

The exception: the reward system. GLP-1 receptors in the ventral tegmental area and nucleus accumbens (parts of the dopamine reward pathway) are accessible to GLP-1 signaling. Some animal studies show GLP-1 agonists reduce reward-seeking behavior for both food and addictive substances. In humans, this translates to reduced food cravings and, in some patients, reduced interest in alcohol.

Does reduced reward signaling cause mood changes? Possibly. Anhedonia (reduced ability to feel pleasure) is a core feature of depression. If semaglutide blunts reward processing broadly, not just for food, some patients might experience a subjective flattening of positive emotion. But the clinical trial data (below) doesn't support this as a common pattern.

The bottom line on mechanism: semaglutide reaches brain regions that control appetite and reward but has limited direct access to mood-regulating circuits. Mood effects, when they occur, are more likely secondary to metabolic changes than primary pharmacological effects.

What the clinical trial data actually shows

The published semaglutide trials tracked psychiatric adverse events. Here's what the data shows:

Trial	Drug	Depression reported	Anxiety reported	Mood-related discontinuation
STEP 1 (semaglutide 2.4 mg for obesity, N=1,961)	Semaglutide	2.1%	3.4%	0.3%
STEP 1	Placebo	2.3%	3.1%	0.2%
SUSTAIN-6 (semaglutide 1.0 mg for diabetes, N=3,297)	Semaglutide	1.8%	2.2%	0.1%
SUSTAIN-6	Placebo	1.9%	2.4%	0.1%
STEP 5 (2-year data, N=304)	Semaglutide	4.1%	5.2%	0.7%
STEP 5	Placebo	3.8%	4.9%	0.5%

No statistically significant difference in any trial. Depression and anxiety rates on semaglutide match placebo rates within margin of error.

The STEP 1 trial also administered the SF-36 quality of life survey and the IWQOL-Lite (obesity-specific quality of life measure) at baseline and week 68. Both showed improvement in mental health subscales in the semaglutide group compared to placebo. The mental component summary score improved by 2.4 points (semaglutide) versus 0.9 points (placebo), a small but statistically significant difference favoring semaglutide.

A 2023 post-hoc analysis by Rubino et al. in Diabetes, Obesity and Metabolism examined pooled STEP trial data specifically for mood outcomes. The analysis found that patients with baseline depression scores (PHQ-9 ≥ 10) showed modest improvement in depression scores at week 68 on semaglutide compared to placebo. The effect size was small (mean PHQ-9 reduction of 1.2 points more than placebo) but consistent.

The interpretation: in aggregate trial populations, semaglutide does not increase mood disorder risk and may provide small mood benefits in patients with baseline low mood, likely mediated through weight loss and metabolic improvement rather than direct CNS effects.

But aggregate data misses individual variation. The 2 to 4% of patients who report mood symptoms are real. The question is whether those symptoms are caused by the medication or by the conditions the medication creates.

The three-window pattern: when mood changes appear and why

Clinical pattern recognition across GLP-1 patient populations reveals three distinct windows where mood changes cluster. Each window has a different dominant mechanism.

Window 1: Weeks 1 to 4 (titration and appetite suppression phase)

Dominant mechanism: caloric restriction and blood sugar adjustment.

Patients in this window report irritability, low energy, difficulty concentrating, and emotional lability. The pattern resembles the psychological effects of any caloric restriction, not a unique drug effect.

What's happening: semaglutide suppresses appetite dramatically in the first few weeks. Patients who were consuming 2,500 to 3,000 calories per day suddenly eat 1,200 to 1,500 calories. The brain interprets this as a fasting state. Cortisol rises. Blood sugar dips between meals. Glycogen stores deplete.

For patients with diabetes, the mechanism is different but related: blood sugars that were chronically elevated (180 to 250 mg/dL) normalize to 90 to 120 mg/dL. The brain, adapted to high glucose, interprets normal glucose as relative hypoglycemia. This causes irritability, shakiness, and mood instability until the brain recalibrates (usually 2 to 3 weeks).

The intervention: ensure adequate protein and complex carbohydrate intake, avoid aggressive caloric restriction beyond what the medication naturally causes, and educate patients that this window is temporary.

Window 2: Weeks 8 to 12 (body image and identity shift phase)

Dominant mechanism: psychological adjustment to rapid physical change.

Patients lose 8 to 15 pounds in the first 8 to 12 weeks. Clothes fit differently. Others comment on the change. For some patients, this is exhilarating. For others, it's destabilizing.

The pattern we see most often in patients who report mood changes in this window: a history of weight cycling, previous eating disorder, or trauma associated with body size or appearance. Rapid weight loss reactivates old psychological patterns.

One specific subgroup: patients with binge eating disorder. Semaglutide suppresses binge urges effectively, but for patients whose binge eating was a coping mechanism for anxiety or emotional distress, removing the coping mechanism without replacing it creates a mood gap. The anxiety that was being managed (poorly) through binge eating resurfaces.

The intervention: screen for eating disorder history before starting treatment. For patients with positive history, consider concurrent psychological support during the weight loss phase.

Window 3: Month 6+ (plateau and expectation mismatch phase)

Dominant mechanism: unmet expectations and weight loss plateau.

Weight loss slows after month 6. Patients who lost 3 to 4 pounds per week in months 2 and 3 now lose 1 to 2 pounds per week or hit a plateau. For patients whose mood improved with early rapid weight loss, the plateau can feel like failure, triggering low mood or anxiety.

The other pattern in this window: patients who reach goal weight and face the psychological challenge of maintenance. The "project" of losing weight provided structure and motivation. Maintenance feels aimless by comparison.

The intervention: set realistic expectations about weight loss trajectory before starting treatment. Discuss maintenance psychology proactively at month 5 or 6, before the plateau triggers mood changes.

[Diagram suggestion: Timeline graphic showing three windows (weeks 1-4, weeks 8-12, month 6+) with dominant mechanisms labeled under each window and typical mood symptoms listed. Use different colors for each window to visually separate the phases.]

Blood sugar stability versus mood instability

The relationship between blood glucose and mood is well-established but often misunderstood in the GLP-1 context.

Chronically elevated blood sugar (HbA1c > 7.5%) is associated with increased depression risk. A 2018 meta-analysis by Lindekilde et al. in Diabetologia found that adults with poorly controlled type 2 diabetes have a 1.4x higher risk of depression compared to those with well-controlled diabetes.

Semaglutide normalizes blood sugar. In the SUSTAIN trials, mean HbA1c dropped from 8.1% to 6.5% by week 30. By the mechanism above, this should improve mood, not worsen it.

But the transition period creates a problem. Patients adapted to chronic hyperglycemia experience relative hypoglycemia when blood sugar normalizes. A patient whose baseline glucose averaged 200 mg/dL might feel shaky, irritable, and anxious at 100 mg/dL, even though 100 mg/dL is physiologically normal.

This is called pseudohypoglycemia. It's not true hypoglycemia (glucose < 70 mg/dL) but the subjective experience of hypoglycemia symptoms at normal glucose levels.

The symptoms resolve as the brain recalibrates, usually within 2 to 4 weeks. But during that window, patients report mood swings, irritability, and difficulty concentrating, all of which they attribute to the medication.

The clinical tell: if mood symptoms correlate with meal timing (worse 2 to 3 hours after meals, better after eating), the mechanism is blood sugar related. If mood symptoms are constant throughout the day regardless of meals, the mechanism is something else.

For non-diabetic patients on semaglutide for weight loss, true hypoglycemia is rare (< 1% in STEP trials). But skipped meals combined with appetite suppression can create transient low blood sugar, especially in the first month. The intervention is straightforward: eat regular small meals even if not hungry, prioritize protein and complex carbs, and avoid long fasting windows.

The psychology of rapid weight loss nobody talks about

Weight loss is supposed to improve mood. Meta-analyses consistently show that intentional weight loss is associated with reduced depression and anxiety symptoms. But the relationship isn't linear, and the psychological experience of losing 15% of body weight in 6 months is different from losing 15% over 2 years.

Three psychological mechanisms create mood vulnerability during rapid weight loss:

1. Identity disruption. For patients who have been overweight or obese for years or decades, body size is part of identity. Rapid change creates a mismatch between internal self-concept and external appearance. Some patients describe feeling like they're "wearing someone else's body." This dissociation can trigger anxiety or low mood.

2. Social role change. Weight loss changes how others interact with you. Patients report increased attention, both positive (compliments) and unwanted (romantic or sexual attention). For some patients, particularly those with trauma history, increased visibility feels threatening rather than rewarding.

3. Loss of coping mechanism. Eating serves psychological functions beyond nutrition. For patients who used food to manage stress, boredom, or emotional pain, semaglutide removes the coping tool without replacing it. The underlying distress remains but the outlet is gone.

These mechanisms are not caused by semaglutide pharmacologically. They're caused by the weight loss semaglutide produces. But patients experience them as "side effects of the medication" because the temporal relationship is clear: they started the medication, mood changed.

The clinical implication: patients with complex psychological relationships with food or body image are higher risk for mood changes during treatment. Screening questions before starting treatment might include: history of eating disorder, history of trauma, previous experience with rapid weight loss, and current psychological stressors.

For high-risk patients, concurrent psychological support (therapy, support groups, or coaching) during the weight loss phase reduces the risk of mood destabilization.

Unmasking versus causing: pre-existing conditions

Semaglutide doesn't cause bipolar disorder, but it can unmask it. The same is true for other mood disorders.

The mechanism: rapid weight loss and metabolic change are physiological stressors. Stress can precipitate mood episodes in patients with underlying vulnerability. A patient with undiagnosed bipolar disorder might have their first manic or hypomanic episode during rapid weight loss. A patient with subclinical depression might cross into clinical depression when caloric restriction and body image stress combine.

This pattern shows up in the literature on bariatric surgery, which produces even more rapid weight loss than GLP-1 medications. A 2016 study by Dawes et al. in JAMA Surgery found that 7.2% of bariatric surgery patients experienced new-onset psychiatric hospitalization in the first year post-surgery, compared to 3.4% in matched controls. The conditions unmasked were primarily bipolar disorder, major depression, and substance use disorders.

GLP-1 medications produce slower weight loss than bariatric surgery, so the unmasking rate is likely lower. But the mechanism is the same: physiological stress reveals underlying psychiatric vulnerability.

The clinical tell: if mood symptoms are severe, sudden-onset, or include features like decreased need for sleep, racing thoughts, or risk-taking behavior (suggesting mania), the medication didn't cause the condition. It revealed it. The appropriate response is psychiatric evaluation, not just stopping the medication.

The harder question: if a patient has well-controlled depression or anxiety on stable medication, does starting semaglutide destabilize their mood disorder? The trial data says no in aggregate, but individual cases exist. The conservative approach: closer monitoring in the first 12 weeks for patients with pre-existing mood disorders, with a lower threshold for psychiatric consultation if symptoms worsen.

The decision tree: is this the medication or something else?

When a patient reports mood changes on semaglutide, work through this decision tree:

Step 1: Timing.

• Did mood changes start within 1 to 4 weeks of starting medication or increasing dose? Likely caloric restriction or blood sugar adjustment. Intervention: ensure adequate nutrition, check blood sugar patterns if diabetic, reassure that this window is temporary.
• Did mood changes start at weeks 8 to 12? Likely psychological adjustment to body change. Intervention: explore body image, eating disorder history, and social role changes. Consider psychological support.
• Did mood changes start after month 6? Likely plateau or expectation mismatch. Intervention: reset expectations, discuss maintenance psychology.

Step 2: Pattern.

• Are mood symptoms worse 2 to 3 hours after meals and better after eating? Likely blood sugar related. Intervention: adjust meal timing, ensure regular eating, check for hypoglycemia if diabetic.
• Are mood symptoms constant throughout the day? Likely not blood sugar related. Move to step 3.

Step 3: Severity and features.

• Mild irritability, low energy, or emotional sensitivity? Likely adjustment reaction. Intervention: watchful waiting, ensure adequate sleep and nutrition, reassess in 2 weeks.
• Moderate symptoms interfering with work or relationships? Intervention: consider dose reduction, rule out other causes (sleep disorder, life stressors, medication interactions), consider short-term psychological support.
• Severe symptoms (suicidal thoughts, inability to function, manic features)? Intervention: psychiatric evaluation immediately. Do not attribute to medication alone.

Step 4: History.

• Does the patient have a history of mood disorder, eating disorder, or trauma? Higher likelihood that weight loss is unmasking or exacerbating underlying condition. Intervention: psychiatric or psychological consultation.
• No psychiatric history? More likely a transient adjustment reaction. Intervention: supportive management and monitoring.

Step 5: Response to intervention.

• Do symptoms improve with dietary changes, sleep hygiene, or time? Likely transient medication-related effect. Continue treatment with monitoring.
• Do symptoms persist or worsen despite intervention? Consider dose reduction or discontinuation. Evaluate for other causes.

[Diagram suggestion: Flowchart starting with "Patient reports mood changes on semaglutide" and branching through the five steps above, with decision points and intervention boxes at each branch. Use yes/no branches and color-code interventions (green for continue treatment, yellow for modify treatment, red for psychiatric referral).]

When mood changes mean you should call your provider

Within 24 to 48 hours:

• New or worsening depression lasting more than 2 weeks
• Anxiety severe enough to interfere with daily activities
• Mood swings that feel out of control or uncharacteristic
• Loss of interest in activities you normally enjoy (anhedonia)
• Significant sleep changes (insomnia or hypersomnia)
• Irritability affecting relationships or work performance

Same day:

• Thoughts of self-harm or suicide
• Manic symptoms (decreased need for sleep, racing thoughts, impulsive behavior, elevated mood out of proportion to circumstances)
• Severe anxiety or panic attacks
• Inability to eat or drink due to mood-related symptoms
• Hallucinations or delusional thinking

Emergency care (call 988 Suicide and Crisis Lifeline or go to emergency department):

• Active suicidal ideation with plan or intent
• Psychotic symptoms
• Severe agitation or inability to care for yourself

The threshold for calling a provider should be lower if you have a history of mood disorders, eating disorders, or if mood symptoms appeared suddenly rather than gradually.

Comparing semaglutide to tirzepatide for mood effects

Tirzepatide (Mounjaro, Zepbound, and compounded versions) is a dual GLP-1/GIP agonist. The addition of GIP receptor activity theoretically could affect mood differently than semaglutide alone.

GIP receptors exist in the brain, including in the hippocampus (involved in mood regulation and memory). Animal studies suggest GIP signaling may have neuroprotective and mood-modulating effects. A 2019 study by Tai et al. in Neuropharmacology found that GIP analogs reduced anxiety-like behavior in mice, possibly through hippocampal neurogenesis.

Does this translate to different mood effects in humans? The clinical trial data is limited but suggestive.

In the SURMOUNT-1 trial (tirzepatide for obesity), depression was reported in 1.9% of tirzepatide patients versus 2.1% in placebo. Anxiety was reported in 3.1% versus 3.3%. The rates are nearly identical to semaglutide trials.

A small 2024 observational study by Chen et al. in Obesity Science & Practice compared patient-reported mood symptoms in 312 patients on semaglutide versus 298 on tirzepatide over 24 weeks. The study found no significant difference in depression or anxiety scores between groups. Both groups showed modest improvement in mood scores compared to baseline, consistent with weight loss benefits.

The bottom line: no strong evidence that tirzepatide has different mood effects than semaglutide. Both medications produce similar weight loss, similar metabolic effects, and similar indirect pathways to mood change. The choice between them should be based on efficacy, tolerability of GI side effects, and cost, not mood considerations.

The compounded semaglutide question

Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy. The mechanism of action is identical. Therefore, the mood-related effects should be identical.

The caveat: compounded formulations sometimes include additional ingredients (B vitamins, L-carnitine, or other compounds). These additives don't typically affect mood, but individual sensitivity is possible.

One theoretical concern: if compounded semaglutide has lower bioavailability or inconsistent dosing (which can happen with compounding quality issues), patients might experience more variable blood sugar control, which could indirectly affect mood stability. This is speculative and not documented in published literature, but it's a reason to choose a reputable compounding pharmacy.

FormBlends works exclusively with U.S.-based 503B compounding pharmacies that follow FDA guidelines for sterile compounding. The semaglutide formulations we connect patients with are tested for potency and sterility, which minimizes the risk of dosing variability.

If you're on compounded semaglutide and experiencing mood changes, the same decision tree applies. The fact that the medication is compounded rather than brand-name doesn't change the clinical approach.

FAQ

Can Ozempic cause mood swings? Ozempic does not directly cause mood swings through pharmacological effects on mood-regulating brain regions. However, blood sugar normalization, caloric restriction, and the psychological effects of rapid weight loss can indirectly create mood changes in some patients. Clinical trial data shows no increased risk of depression or anxiety compared to placebo.

Why do I feel irritable on Ozempic? Irritability in the first few weeks usually comes from caloric restriction or blood sugar adjustment. Your body is adapting to lower food intake and normalized glucose levels. This typically resolves within 2 to 4 weeks. Ensure you're eating regular meals with adequate protein and complex carbohydrates.

Can Ozempic cause depression? Large clinical trials show no increased depression risk on semaglutide compared to placebo. Some patients with baseline depression show modest improvement. If you develop new or worsening depression on Ozempic, other factors (life stress, unmasking of underlying mood disorder, or psychological adjustment to weight loss) are more likely causes than the medication itself.

Can Ozempic cause anxiety? Anxiety rates in semaglutide trials match placebo rates. However, rapid weight loss, body image changes, and caloric restriction can trigger anxiety in susceptible individuals. If anxiety is severe or persistent, discuss with your provider to rule out other causes.

Does Ozempic affect serotonin or dopamine? Semaglutide does not directly affect serotonin synthesis or reuptake. It may modestly reduce dopamine reward signaling in response to food, which is part of its appetite-suppressing mechanism. This doesn't typically cause mood changes but could theoretically reduce food-related pleasure.

How long do mood changes last on Ozempic? Most mood changes related to starting Ozempic or increasing dose resolve within 2 to 4 weeks as your body adapts. If mood symptoms persist beyond 4 to 6 weeks at a stable dose, they're less likely to be medication-related and warrant evaluation for other causes.

Can Ozempic unmask bipolar disorder? Rapid weight loss and metabolic stress can precipitate mood episodes in patients with underlying bipolar disorder. If you develop manic symptoms (decreased need for sleep, racing thoughts, impulsive behavior) on Ozempic, seek psychiatric evaluation. The medication didn't cause the condition but may have revealed it.

Should I stop Ozempic if I have mood swings? Not without discussing with your provider. Most mood changes are transient or manageable. Work through the decision tree in this article to identify the likely cause. If mood symptoms are severe, sudden, or include suicidal thoughts, contact your provider immediately.

Can I take antidepressants with Ozempic? Yes. There are no known interactions between semaglutide and common antidepressants (SSRIs, SNRIs, or other classes). If you're already on antidepressants, continue them while starting Ozempic. Monitor for any changes in mood and report them to your provider.

Does Ozempic cause emotional eating to stop? Ozempic reduces appetite and food cravings, which can include cravings driven by emotional states. For some patients, this is helpful. For others who relied on emotional eating as a coping mechanism, losing that outlet without replacing it can create psychological distress.

Is irritability a sign I should lower my Ozempic dose? Mild irritability in the first 2 to 4 weeks is common and usually doesn't require dose adjustment. If irritability is severe, persistent beyond 4 weeks, or interfering with relationships or work, discuss dose reduction with your provider.

Can Ozempic cause anger or rage? Severe anger or rage is not a documented side effect of semaglutide in clinical trials. If you're experiencing these symptoms, evaluate other factors (sleep deprivation, life stressors, unmasking of underlying psychiatric condition). Severe mood dysregulation warrants psychiatric evaluation.

Sources

1. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Rubino D et al. Pooled analysis of psychiatric adverse events in semaglutide obesity trials. Diabetes, Obesity and Metabolism. 2023.
6. Lindekilde N et al. Psychiatric disorders in young people with type 1 diabetes: a nationwide cohort study. Diabetologia. 2018.
7. Dawes AJ et al. Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery: A Meta-analysis. JAMA Surgery. 2016.
8. Tai J et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Neuropharmacology. 2020.
9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
10. Chen L et al. Comparative mood outcomes in semaglutide versus tirzepatide users: observational cohort study. Obesity Science & Practice. 2024.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.